Andreas Wannhoff

Andreas Wannhoff

Auto-generated profile, based on publicly available information

Andreas Wannhoff

RKH Klinikum Ludwigsburg, GERMANY

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in Journal of Hepatology
Verified
Journal Article
Closed access
AWAndreas Wannhoff
Andreas Wannhoff
JHJohannes Roksund Hov
Johannes Roksund Hov
TFTrine Folseraas
Trine Folseraas
CRChristian Rupp
Christian Rupp
KFKilian Friedrich
Kilian Friedrich
DGDaniel Nils Gotthardt
Daniel Nils Gotthardt

1 September 2016 in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Verified
Journal Article
Open access
Wolfgang StremmelWolfgang Stremmel
Wolfgang Stremmel
SSSimone Staffer
Simone Staffer
HGHongying Gan-Schreier
Hongying Gan-Schreier
AWAndreas Wannhoff
Andreas Wannhoff
MBMargund Bach
Margund Bach
AGAnnika Gauss
Annika Gauss
Phosphatidylcholine (PC) is the most abundant phospholipid in intestinal mucus, indicative of a specific transport system across the mucosal epithelium to the intestinal lumen. To elucidate this transport mechanism, we employed a transwell tissue culture system with polarized CaCo2 cells. It was shown that PC could not substantially be internalized by the cells. However, after basal application of increasing PC concentrations, an apical transport of 47.1±6.3nmolh(-1)mMPC(-1) was observed. Equilibrium distribution studies with PC applied in equal concentrations to the basal and apical compartments showed a 1.5-fold accumulation on the expense of basal PC. Disruption of tight junctions (TJ) by acetaldehyde or PPARγ inhibitors or by treatment with siRNA to TJ proteins suppressed paracellular transport by at least 50%. Transport was specific for the choline containing the phospholipids PC, lysoPC and sphingomyelin. We showed that translocation is driven by an electrochemical gradient generated by apical accumulation of Cl(-) and HCO3(-) through CFTR. Pretreatment with siRNA to mucin 3 which anchors in the apical plasma membrane of mucosal cells inhibited the final step of luminal PC secretion. PC accumulates in intestinal mucus using a paracellular, apically directed transport route across TJs.

27 January 2019 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
AWAndreas Wannhoff
Andreas Wannhoff
MBMaik Brune
Maik Brune
JKJohannes Knierim
Johannes Knierim
KWKarl Heinz Weiss
Karl Heinz Weiss
CRChristian Rupp
Christian Rupp
DGDaniel N. Gotthardt
Daniel N. Gotthardt
Summary: Background: Primary sclerosing cholangitis is associated with an increased risk of biliary tract cancer. Carbohydrate antigen 19‐9 (CA19‐9) can be used to screen for these malignancies.Aim: To perform a longitudinal analysis of CA19‐9 in patients with primary sclerosing cholangitis.Methods: We conducted a retrospective analysis of CA19‐9 values in patients who had primary sclerosing cholangitis, with and without biliary malignancy. We calculated the index of individuality and reference change value in patients who were cancer‐free. Long‐term analysis of CA19‐9 in cancer‐free patients was performed and we assessed the change of CA19‐9 prior to diagnosis of cancer.Results: We obtained 1818 CA19‐9 values from 247 patients, including 32 with malignancy. Median CA19‐9 in cancer‐free individuals was 15.6 U/mL. The index of individuality was 0.37 and the reference change value was 46.23%. In cancer‐free patients, no significant change in CA19‐9 was observed at 1, 2, 5, 7, 10, 15, and 20 years after initial diagnosis of primary sclerosing cholangitis. In patients with biliary tract cancer, CA19‐9 was higher at 3 months prior to diagnosis (P < 0.05) than at 6 months before diagnosis and was also higher than at 3 months prior to last follow‐up in cancer‐free patients (P < 0.05). In 92.9% of patients with biliary cancer, we found an increase in CA19‐9 of >46.23% in the year prior to cancer diagnosis.Conclusions: CA19‐9 in patients with primary sclerosing cholangitis is highly individual, and the reference change value should be preferred to reference intervals. In this study, CA19‐9 remained stable in patients who were cancer‐free but increased early in those who developed biliary tract cancer. Regular CA19‐9 measurement might improve early detection of these malignancies.

30 August 2024 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
AWAndreas Wannhoff
Andreas Wannhoff
KKKonstantinos Kouladouros
Konstantinos Kouladouros
RKRonald Koschny
Ronald Koschny
BWBenjamin Walter
Benjamin Walter
ZZZita Zoll
Zita Zoll
DWDörte Wichmann
Dörte Wichmann

13 March 2025 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
AWAndreas Wannhoff
Andreas Wannhoff
ZNZaheer Nabi
Zaheer Nabi
LMLeon M.G. Moons
Leon M.G. Moons
GHGregory Haber
Gregory Haber
PGPhillip S. Ge
Phillip S. Ge
KCKarel Caca
Karel Caca
INTRODUCTION: Nonexposed endoscopic full-thickness resection (EFTR) using a dedicated full-thickness resection device can be used to perform en bloc resection of subepithelial lesions throughout the gastrointestinal tract. In this article, we aim to evaluate the safety and efficacy of EFTR for the management of duodenal neuroendocrine tumors (dNETs). METHODS: This was an international multicenter retrospective study of device-assisted EFTR for dNET. Study outcomes included rates of technical success, R0 resection, and adverse events (AEs). RESULTS: A total of 171 patients were included across 35 centers. Lesions had a median size of 10 mm and were in the duodenal bulb in 143 cases (83.6%). Technical success was achieved in 164 (95.9%) and R0 resection in 123 cases (71.9%). The R0 resection rate for lesions located in the proximal third of the bulb was 62.0% compared with 83.9% for more distal locations ( P = 0.002). The R0 resection rate was not affected by lesion size or depth of invasion. On multivariable analysis, date of resection (2021 onward) and location distal to the proximal third of the duodenal bulb were independent predictors of R0 resection, but not case volume per participating center. Follow-up information was available for 114 patients (66.7%) and demonstrated 2 recurrences over a median follow-up of 10 months. Severe AEs occurred in 3 patients (1.8%). DISCUSSION: EFTR of dNET showed high technical success and R0 resection rates and very low rate of severe AEs. It could become endoscopic treatment of choice for dNET, at least for lesions not within proximity of the pylorus.

11 March 2016 in Hepatology
Verified
Journal Article
Open access
PDF file
KFKilian Friedrich
Kilian Friedrich
MSMark Smit
Mark Smit
MBMaik Brune
Maik Brune
TGThomas Giese
Thomas Giese
CRChristian Rupp
Christian Rupp
DGDaniel Nils Gotthardt
Daniel Nils Gotthardt
The pathogenesis of intrahepatic biliary stricture formation in patients with primary sclerosing cholangitis (PSC) or after liver transplantation (LTx) remains elusive. CD14 receptor signaling is a key mediator of the innate immune system; its common genetic variant is associated with alcoholic liver disease. PSC and LTx cohort patients and primary biliary cirrhosis (PBC) control patients were genotyped for the CD14 -260C>T (rs2569190) polymorphism, and genotypes were correlated with long-term clinical outcome. Biliary tissue, bile, and whole blood of PSC patients and healthy controls were screened for markers of the innate immune system and bacterial infection. In 121 PSC patients, the CD14 -260C>T genotype was associated with development of dominant bile duct strictures (P = 0.02). In 365 LTx patients, TT carriers (4.1%) were protected against the formation of nonanastomotic biliary strictures versus CC/CT patients (12.6%; P = 0.01). Chemokine ligand 8 (P = 0.04) and chemokine receptor 6 (P = 0.004) were up-regulated in biliary tissue of PSC patients with the TT versus the CC/CT genotype. Lipopolysaccharide whole-blood stimulation resulted in a significant change in interleukin (IL)-8 (P = 0.05) and IL-12p40 levels (P = 0.04) in healthy control subjects carrying the TT genotype. TT PSC patients were protected against Gram-negative bacterial biliary infection (TT: 0% vs. CC/CT: 22.5%; P = 0.02). Serum-soluble CD14 levels correlated with the CD14 -260C>T genotype (P = 0.02), representing an independent risk indicator of survival in PSC patients (hazard ratio, 0.40; 95% confidence interval, 0.19-0.86; P =0.01). Conclusions: The function of the innate immune response by CD14 is crucial during biliary infection and stricture formation. The benefits of CD14 signaling modification should be addressed in future studies. (Hepatology 2016;64:843-852)